Published in Cancer Chemother Pharmacol on January 01, 1999
Crystal structure of 9-amino-N-[2-(4-morpholinyl)ethyl]-4-acridinecarboxamide bound to d(CGTACG)2: implications for structure-activity relationships of acridinecarboxamide topoisomerase poisons. Nucleic Acids Res (2002) 1.23
Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes. Br J Clin Pharmacol (2001) 0.78
5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy. Invest New Drugs (2002) 0.78
DNA-directed alkylating agents. 6. Synthesis and antitumor activity of DNA minor groove-targeted aniline mustard analogues of pibenzimol (Hoechst 33258) J Med Chem (1994) 1.93
A new factor in the production and cure of macrocytic anaemias and its relation to other haemopoietic principles curative in pernicious anaemia. Biochem J (1937) 1.89
Multiple patterns of resistance of human leukemia cell sublines to amsacrine analogues. J Natl Cancer Inst (1990) 1.57
Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J Med Chem (1991) 1.51
Papulacandin B: an inhibitor of glucan synthesis in yeast spheroplasts. Eur J Biochem (1979) 1.49
Blood flow failure as a major determinant in the antitumor action of flavone acetic acid. J Natl Cancer Inst (1989) 1.49
Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer. J Clin Oncol (1987) 1.47
Structure of a mammalian serine tRNA. Nature (1968) 1.41
Carbon monoxide diffusing capacity is a poor predictor of clinically significant bleomycin lung. New Zealand Clinical Oncology Group. J Clin Oncol (1990) 1.39
Adjuvant chemotherapy for non-metastatic osteosarcoma of the extremities in two New Zealand cancer centres. Aust N Z J Med (1995) 1.38
Differences in expression of lupus nephritis in New Zealand mixed H-2z homozygous inbred strains of mice derived from New Zealand black and New Zealand white mice. Origins and initial characterization. Lab Invest (1993) 1.38
Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours. Eur J Cancer Clin Oncol (1987) 1.33
Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma. Cancer Treat Rep (1983) 1.32
Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid. Br J Cancer (2002) 1.32
Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice. Cancer Res (1991) 1.30
Quenching of DNA-ethidium fluorescence by amsacrine and other antitumor agents: a possible electron-transfer effect. Biochemistry (1984) 1.29
Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol (1995) 1.26
Effect of flavone acetic acid on Lewis lung carcinoma: evidence for an indirect effect. J Natl Cancer Inst (1988) 1.26
Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. Cancer Res (1999) 1.24
Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer Res (1999) 1.22
Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes. Cancer Chemother Pharmacol (2000) 1.22
Nonintercalative DNA-binding antitumour compounds. Mol Cell Biochem (1982) 1.21
The interaction of ethidium with synthetic double-stranded polynucleotides at low ionic strength. Nucleic Acids Res (1978) 1.20
Induction of natural killer cell activity by the antitumour compound flavone acetic acid (NSC 347 512). Eur J Cancer Clin Oncol (1987) 1.20
Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs. Br J Cancer (2000) 1.18
Substrate specificity of adenine-specific transfer RNA methylase in normal and leukemic tissues. Eur J Biochem (1968) 1.17
Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer (1998) 1.16
Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer (2003) 1.15
Potential antitumor agents. 59. Structure-activity relationships for 2-phenylbenzimidazole-4-carboxamides, a new class of "minimal" DNA-intercalating agents which may not act via topoisomerase II. J Med Chem (1990) 1.12
Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncol Res (1994) 1.11
Phenytoin concentrations in mixed, parotid and submandibular saliva and serum measured by radioimmunoassay. Br J Clin Pharmacol (1977) 1.11
Production and characterisation of antisera to diphenylhydantoin suitable for radioimmunoassay. J Immunol Methods (1976) 1.10
Existence of an extended series of antitumor compounds which bind to deoxyribonucleic acid by nonintercalative means. Biochemistry (1980) 1.10
Interaction of the antitumor drug 4'-(9-acridinylamino)methanesulfon-m-anisidide and related acridines with nucleic acids. Mol Pharmacol (1981) 1.09
Potenial antitumor agents. 28. Deoxyribonucleic acid polyintercalating agents. J Med Chem (1978) 1.07
Induction of tumor necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Cancer Res (1994) 1.06
Potential antitumor agents. 51. Synthesis and antitumor activity of substituted phenazine-1-carboxamides. J Med Chem (1987) 1.05
The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice. Br J Cancer (2002) 1.05
Potential antitumor agents. 54. Chromophore requirements for in vivo antitumor activity among the general class of linear tricyclic carboxamides. J Med Chem (1988) 1.04
Salivary phenytoin radioimmunoassay. A simple method of the assessment of non-protein bound drug concentrations. Eur J Clin Pharmacol (1977) 1.03
A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells. Anal Biochem (1984) 1.02
Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo. J Med Chem (1989) 1.02
Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation. Mol Pharmacol (1999) 1.02
Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer. Eur J Cancer (1995) 1.01
Analysis of the TGF beta functional pathway in epithelial ovarian carcinoma. Br J Cancer (2001) 1.00
Evidence for the production of nitric oxide by activated macrophages treated with the antitumor agents flavone-8-acetic acid and xanthenone-4-acetic acid. Cancer Res (1990) 1.00
Nucleolar damage correlates with neurotoxicity induced by different platinum drugs. Br J Cancer (2001) 1.00
A highly sensitive fluorescent microplate method for the determination of UDP-glucuronosyl transferase activity in tissues and placental cell lines. Drug Metab Dispos (2000) 1.00
A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. J Clin Oncol (1991) 0.99
Radiosensitivity of new and established human melanoma cell lines: comparison of [3H]thymidine incorporation and soft agar clonogenic assays. Eur J Cancer (1994) 0.98
Potential antitumor agents. 44. Synthesis and antitumor activity of new classes of diacridines: importance of linker chain rigidity for DNA binding kinetics and biological activity. J Med Chem (1985) 0.98
Measurement of drugs in saliva: a review. Methods Find Exp Clin Pharmacol (1979) 0.98
In vitro methylation of yeast serine transfer ribonucleic acid. Biochemistry (1970) 0.98
Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Res (2001) 0.98
Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice. Br J Cancer (2004) 0.97
Studies on the metabolism of the novel antitumor agent [N-methyl-11C]N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in rats and humans prior to phase I clinical trials. Cancer Res (1997) 0.97
Potential antitumor agents. 50. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. J Med Chem (1987) 0.97
The recovery of immune responsiveness after treatment with cyclophosphamide. Int Arch Allergy Appl Immunol (1971) 0.96
Antitumour responses to flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid in immune deficient mice. Br J Cancer (1992) 0.95
Potential antitumor agents. 57. 2-Phenylquinoline-8-carboxamides as "minimal" DNA-intercalating antitumor agents with in vivo solid tumor activity. J Med Chem (1989) 0.95
A comparison of 1-methyladenine-containing sequences in transfer ribonucleic acid from yeast and from rat liver. Biochemistry (1969) 0.95
Enhancement of in vitro cytotoxicity of mouse peritoneal exudate cells by flavone acetic acid (NSC 347512). Eur J Cancer Clin Oncol (1988) 0.95
Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. Int J Radiat Oncol Biol Phys (1994) 0.94
Light-induced breakdown of flavone acetic acid and xanthenone analogues in solution. J Natl Cancer Inst (1990) 0.94
Carboplatin: a very active new cisplatin analog in the treatment of small cell lung cancer. Cancer Treat Rep (1985) 0.93
From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives. Eur J Cancer (1996) 0.93
Microculture-based chemosensitivity testing: a feasibility study comparing freshly explanted human melanoma cells with human melanoma cell lines. J Natl Cancer Inst (1992) 0.93
Potential antitumor agents. 43. Synthesis and biological activity of dibasic 9-aminoacridine-4-carboxamides, a new class of antitumor agent. J Med Chem (1984) 0.93
Synthesis and cytotoxic activity of 7-oxo-7H-dibenz[f,ij]isoquinoline and 7-oxo-7H-benzo[e]perimidine derivatives. J Med Chem (2001) 0.93
Comparison of in vitro activity of cytotoxic drugs towards human carcinoma and leukaemia cell lines. Eur J Cancer Clin Oncol (1986) 0.93
Ring-substituted 11-oxo-11H-indeno[1,2-b]quinoline-6-carboxamides with similar patterns of cytotoxicity to the dual topo I/II inhibitor DACA. Bioorg Med Chem (1999) 0.92
The morphological effects of the anti-tumor agents flavone acetic acid and 5,6-dimethyl xanthenone acetic acid on the colon 38 mouse tumor. Pathology (1994) 0.91
The specificity of transfer ribonucleic acid methylases from rat liver. Biochemistry (1968) 0.91
Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer (1999) 0.91
Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer (1995) 0.91
The evaluation of a radioimmunoassay for phenothiazines and thioxanthenes using an iodinated tracer. J Immunol Methods (1979) 0.91
Predictors of favorable outcome following naltrexone treatment. Drug Alcohol Depend (1983) 0.91
Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice. Cancer Chemother Pharmacol (1991) 0.91
Risk factors for early hospital readmission after cardiac operations. J Thorac Cardiovasc Surg (2001) 0.91
Plasma nitrate clearance in mice: modeling of the systemic production of nitrate following the induction of nitric oxide synthesis. Cancer Chemother Pharmacol (1995) 0.90
Preclinical prediction of factors influencing the elimination of 5,6-dimethylxanthenone-4-acetic acid, a new anticancer drug. Cancer Res (1997) 0.90
A comparison of the response of human lung carcinoma xenografts to vindesine and vincristine. Br J Cancer (1982) 0.90
17-Oxosteroid conjugates in plasma and urine of patients with acute intermittent porphyria. Clin Sci Mol Med (1974) 0.90
Expression, localisation and activity of ATP binding cassette (ABC) family of drug transporters in human amnion membranes. Placenta (2007) 0.90
Monoclonal antibody to native P39 protein from Borrelia burgdorferi. J Clin Microbiol (1994) 0.90
Potential antitumor agents. 46. Structure-activity relationships for acridine monosubstituted derivatives of the antitumor agent N-[2-(dimethylamino)ethyl]-9-aminoacridine-4-carboxamide. J Med Chem (1986) 0.90
Comparison of transfer RNA and aminoacyl RNA ligases from calf liver and spleen. Biochim Biophys Acta (1966) 0.89
Antitumor activity of XR5944, a novel and potent topoisomerase poison. Anticancer Drugs (2001) 0.89
Flavone acetic acid (FAA) with recombinant interleukin-2 (TIL-2) in advanced malignant melanoma. II: Induction of nitric oxide production. Br J Cancer (1992) 0.89
Beta adrenergic regulation of glycogen phosphorylase activity and adenosine cyclic 3', 5'-monophosphate accumulation in control and desensitized C-6 astrocytoma cells. Mol Pharmacol (1977) 0.89
Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid. Drug Metab Dispos (2000) 0.89
Determination of citrinin in corn and barley. J Assoc Off Anal Chem (1978) 0.89
Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents. Clin Chim Acta (2001) 0.88
DNA-directed alkylating agents. 2. Synthesis and biological activity of platinum complexes linked to 9-anilinoacridine. J Med Chem (1990) 0.88
Melphalan penetration of the blood-brain barrier via the neutral amino acid transporter in tumor-bearing brain. Cancer Res (1992) 0.88
Inpatient alcohol treatment in a private healthcare setting: which patients benefit and at what cost? Am J Addict (1999) 0.87
Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine). Cancer Res (1989) 0.87
Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid. Anticancer Res (1999) 0.87